Table 2.
Main association between acrylamide intake and ovarian cancer risk, 20.3 years of follow-up
| n cases | Per 10 µg/day increment | Quintile 1 | Quintile 2 | Quintile 3 | Quintile 4 | Quintile 5 | p trend | |
|---|---|---|---|---|---|---|---|---|
| HR (95% CI)a | HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | |||
| All women | 373 | 1.06 (0.98–1.16) | Ref (1.00) | 1.07 (0.73–1.54) | 1.10 (0.75–1.61) | 1.05 (0.71–1.53) | 1.38 (0.95–1.99) | 0.13 |
| Never-smoking women | 243 | 1.15 (1.02–1.30) | Ref (1.00) | 1.37 (0.85–2.21) | 1.61 (0.98–2.65) | 1.50 (0.92–2.44) | 1.85 (1.15–2.95) | 0.01 |
Hazard ratios are adjusted for age (years), age at menarche (years), age at menopause (years), parity (n children), ever use of oral contraceptives (yes/no), ever use of postmenopausal hormone treatment (yes/no), height (cm), body mass index (kg/m2), energy intake (kcal/day), and in the analyses for all women: smoking status (never/ex/current smoker), smoking quantity (n cigarettes/day), smoking duration (smoking years)
The median acrylamide intake of the female subcohort in the quintiles was 9.5, 14.0, 17.9, 24.3, and 36.8 μg/day
aHR (95% CI): hazard ratio with corresponding 95% confidence interval